People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Superluminal Medicines, Inc. | — | Biotechnology | Series B | $50.7M | $22.0M | 2024 |
| Spiral Therapeutics Inc | — | Pharma | Series A | $19.4M | $120.5M | 2022 |
DIAMANTIS XYLAS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DIAMANTIS XYLAS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Dylan Morris | 1 | 8 |
| Guy Nohra | 1 | 5 |
| Guy P. Nohra | 1 | 3 |
| CONY D'CRUZ | 1 | 2 |
| Lawrence Fritz | 1 | 2 |
| CATHERINE RIESEN | 1 | 2 |
| HUGO PERIS | 1 | 1 |
| CRAIG RANDALL | 1 | 1 |
| EUGENE DE JUAN | 1 | 1 |
| ANGELA MACFARLANE | 1 | 1 |
| GUY JEAN SAVOIR GARCIA | 1 | 1 |
| ANTHONY ADAMIS | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.